CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...